# OnCo record olmutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olmutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olmutinib" ;
  schema:name "Olmutinib"@en ;
  schema:alternateName "HM61713"@en, "BI 1482694"@en, "Olita" ;
  schema:description "Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."@en ;
  schema:url <https://onco.cc/drugs/olmutinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Olmutinib> ;
  schema:citation <https://en.wikipedia.org/wiki/Olmutinib>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3545110> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Oral third-generation EGFR kinase inhibitor" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/hanmi-pharmaceutical/> ;
  onco:trials <https://onco.cc/trials/nct02485652/>, <https://onco.cc/trials/nct02444819/>, <https://onco.cc/trials/nct03228277/> .